Combination of New Drug to Counter Lung Cancer
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. It usually grows and spreads more slowly than small cell lung cancer. Now the Cancer Research UK has called in a treatment trial of a drug, which would aim to observe how effective a combination of drugs is in tacking NSCLC. The investigation would be split in two stages and would take place across UK. NSCLC accounts for around 85% of lung cancer cases. The survival rates for people suffering from NSCLC are also low, but it is hoped that these trial would help in uplifting that number.
People with NSCLC and solid tumors were given the same treatment initially. In this trial the patients with solid tumors would be initially administered with vandetanib and an investigational drug called selumentinib. After that people with NSCLC would receive the same combination.
Chief Investigator of the study, Dr. Denis Talbot said, "Therapies for lung cancer often become ineffective because the disease becomes resistant to treatment". But there has been a decline in the number due to advancement in chemotherapy, radiotherapy and drugs, the introduction of screening and better delivery of cancer diagnosis and treatment by the NHS.
New Zealand News
- Porsche reportedly developing electric version of 718 sports car
- Tesla Model Y Performance becomes little bit more expensive to order in China
- Porsche’s recently unveiled Mission R Concept previews electric race cars of future
- Chinese manufacturer GAC’s Aion V e-SUV can charge 0-80% in just 8 minutes
- Oshidori International exits Japanese casino race, citing serious ethical irregularities
- Plug-in cars’ share grows to 32% in Netherlands in September 2021
- Italian motorcycle racer Valentino Rossi enters e-bike business with VR46 MTB range
- Micro Mobility shows off production version of Microlino 2.0 and 3-wheeled e-scooter
- Chinese electric motorcycle maker Evoke Motorcycles to set up shops in Spain
- TenneT adds more electric BMWs to study use of EVs to support power grids